A randomized controlled trial comparing the efficacy and safety of oral tofacitinib versus methotrexate in moderate to severe alopecia areata
Published: 6 January 2025| Version 1 | DOI: 10.17632/zzxxnswhyz.1
Contributor:
Hema latha MudeDescription
My research hypothesis is that methotrexate is non-inferior to tofacitinib in treating moderate to severe alopecia areata. In our research, we evaluated the SALT score, Scalp hair assessment PRO score at every month, and DLQI, and PHQ scores at baseline, at 6 months and 9 months of study period. we also evaluated side effects of both drugs at each visit.
Files
Institutions
Post Graduate Institute of Medical Education and Research Department of Dermatology Venereology and Leprology
Categories
Alopecia Areata